<DOC>
	<DOCNO>NCT02333513</DOCNO>
	<brief_summary>This trial aim evaluate safety effectiveness PCV chemotherapy patient recurrent high-grade glioma IDH1/2 mutation .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness PCV Chemotherapy Patients With Recurrent High-grade Glioma With IDH1/2 Mutation</brief_title>
	<detailed_description>This trial aim evaluate safety effectiveness PCV chemotherapy patient recurrent high-grade glioma IDH1/2 mutation . And , trial approve medical ethic committee hebei yanda hospital . Also , trial get registry code `` ChiCTR-OOC-15005759 '' China clinical trial registry . Researchers conduct thsi trial 2015/02 2017/12 , 100 recurrent high-grade glioma IDH1/2 mutation patient recruit . Patients recruit get PCV chemotherapy ether Hebei Yanda Hospital Beijing Tiantan hospital , get follow-ups clinician .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>A diagnosis highgrade glioma establish pathological method , recurrency disease ongoing . The report pathological diagnosis contain status IDH gene , show IDH1/2 mutation exist . The age patient 18 year old 70 year old . The condition patient permit procedure chemotherapy use PCV schema . The patient informed consent , willing join research . The diagnosis recurrent highgrade glioma . The diagnosis highgrade glioma establish pathological method . No molecular neuropathological report available , report show IDH1/2 mutation exist . The age patient meet requirement research . The condition patient permit procedure chemotherapy use PCV schema . There condition clinician believe PCV chemotherapy appropriate patient . The patient willing join research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>